Patients benefit as innovation flourishes and acceptance spreads

 
 

The European market has come a long way since we launched Hanway in early 2017. From a handful of operators scattered across a number of countries, it has blossomed into a thriving ecosystem with regional hubs, government support, active medical access programmes, growing patient numbers and dedicated infrastructure to ensure cannabis medicines make their way safely and efficiently into the hands of patients.

The team at First Wednesdays (FW), part of The Hanway Company, has been working to create a map of the leading companies in the European medical cannabis ecosystem. They have highlighted market developments and provided further evidence of the rapidly evolving medical cannabis market in Europe.

Report_style_mockup_extra_design1_Linkedin (1).jpg

From plant to patient, the FW ecosystem identifies the key European players based on a publicly available methodology. This has been combined with Hanway insights into each part of the medical cannabis supply chain ranging from genetics to distribution.

Alongside these we have created a timeline of key catalysts for patient access, an insight into medical cannabis dispensing, the European medical cannabis research landscape, the different cannabis production models used by European countries, and a detailed overview of isolated cannabinoids. Finally, an in-depth analysis of the Danish medical cannabis market is provided through a collaboration with Invest in Denmark, part of the Ministry of Foreign Affairs.

The key areas where we identify value over the coming years are in implementing innovative clinical data capturing techniques to conciliate  regulators, developing comprehensive, multi-country sales and marketing strategies to differentiate products, developing partnerships with mainstream pharma and healthcare entrants to the sector, and identifying suitable M&A targets.


 
 

For introductions to any of the companies included in this report, or to hear more about the strategic consultancy services Hanway Associates provides to medical cannabis clients, please get in touch. If you are interested in exploring cultivation opportunities and partners, our CROP17 venture can advise.



 
 




Previous
Previous

EU court rules that CBD is not a narcotic

Next
Next

Big changes may be coming for European CBD regulation. Here’s what you need to know